$LQDA

Bloch Stephen M sold $2.0M of LQDA (indirect holdings)

Bloch Stephen M sold 25,000 indirectly-held shares of Liquidia Corp (LQDA) at an average of $79.47 ($79.45–$80.04, $1.99M total) across 2 trades on 2026-07-01.

Original reporting
SEC EDGAR · Bloch Stephen M
Published Jul 6, 2026, 9:44 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 6, 2026, 9:48 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
medium confidence
Mentioned
$LQDA
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The newest fact is the disclosed sale of 25,000 shares at ~$79.47–$80.05 per share totaling ~$1.99M, with holdings after the sale of 855,073 shares.

02

Market read

Traders may monitor for follow-on insider activity, but this filing alone is not a fundamental catalyst.

03

What to watch

The article does not state whether the sale was part of a broader pattern, tax event, or diversification; it also provides no context on total insider holdings beyond the post-transaction figure.

Relevance 6/10Novelty 3/10Timing: after-hours/filing update (Form 4 filed 2026-07-06)

Background

The article is a SEC Form 4 insider transaction disclosure for Liquidia Corp (LQDA).

Company-level read

Ticker impact

$LQDANeutralMedium confidence
Context

Liquidia Corp director Stephen M. Bloch sold $1.99M of LQDA via an open-market sale under a Form 4 filed July 6.

Expected impact

Likely limited near-term impact; any move would be sentiment-driven rather than catalyst-driven.

Evidence & confidence

The filing is a routine Form 4 open-market sale (no 10b5-1 plan stated) with no accompanying company-specific operational or financial update.

Market effects

No clear sector read-through; this is a single-insider transaction in a biotech/healthcare name.

None indicated.

None indicated.

Counterpoint

Insider sales can be pre-planned for liquidity/tax and may not reflect bearish expectations, especially when the transaction details are limited.

Key entities

  • Liquidia Corp

    Subject of the Form 4 insider transaction disclosure (LQDA).

  • Stephen M. Bloch

    Director who reported an indirect open-market sale of LQDA shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

Liquidia Jumps 6.3% After HC Wainwright & Co. Maintains Buy

Liquidia Corporation (LQDA) rose 6.3% to $36.27 after four firms raised price targets, with an average of $57. HC Wainwright & Co. maintained a Buy rating, lifting its target to $65. The upgrades reflect optimism about the company's prospects and pipeline potential, with a 29.0% average target increase. LQDA's market cap is $3.2B.

$LQDAMedAI 8/10

Morrisville’s Liquidia Settles All Litigation With United Therapeutics, Keeping YUTREPIA Available for PAH Patients

Liquidia Corporation settled all litigation with United Therapeutics, resolving six lawsuits. The agreement allows YUTREPIA, a treatment for pulmonary arterial hypertension, to remain available. Liquidia will pay $380.7 million across 2026 and 2027, funded by YUTREPIA sales and cash on hand. The company reported $222.7 million in YUTREPIA net sales for Q3 2026 and has $396.1 million in cash.

$LQDAMed

H.C. Wainwright raises Liquidia stock price target on settlement

H.C. Wainwright raised its price target for Liquidia Technologies (LQDA) to $65 from $58, maintaining a Buy rating. The stock has surged 21% over the past week following a settlement with United Therapeutics, resolving all pending lawsuits. The settlement removes litigation overhang and allows Liquidia to focus on its pipeline. Analysts have mixed outlooks on the company's future performance.